Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.55 |
| ▸ | ABL1 | P00519 | 6/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.43 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.43 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.43 |
| ▸ | GABRP | O00591 | 2/20 | 0.43 |
| ▸ | GABRD | O14764 | 2/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.43 |
| ▸ | GABRE | P78334 | 2/20 | 0.43 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.43 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.43 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL212757 | 0.94 | LCK (0.55) | LCKABL1MAPK1MAPTGABRA1 | |
| SCHEMBL1535240 | 0.83 | LCK (0.60) | LCKMAPK1MAPTGABRA1GABRG2 | |
| SCHEMBL12552412 | 0.83 | LCK (0.56) | LCKMAPK1MAPTGABRA1GABRG2 | |
| SCHEMBL31413462 | 0.81 | LCK (0.55) | LCKABL1MAPK1MAPTGABRA1 | |
| SCHEMBL1202624 | 0.81 | LCK (0.55) | LCKMAPK1MAPTGABRA1GABRG2 | |
| SCHEMBL740718 | 0.81 | LCK (0.55) | LCKABL1MAPK1MAPTGABRA1 | |
| SCHEMBL27144994 | 0.81 | LCK (0.55) | LCKABL1MAPK1MAPTGABRA1 | |
| SCHEMBL214090 | 0.80 | LCK (0.56) | LCKMAPK1MAPTGABRA1GABRG2 | |
| SCHEMBL12035783 | 0.80 | KDM4E (0.49) | ABL1MAPTKDM4EALDH1A1LMNA | |
| SCHEMBL29840564 | 0.80 | LCK (0.56) | LCKMAPK1MAPTGABRA1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962627-B2 | Oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors | PRESTWICK CHEMICAL, INC. (FR) | 2015-02-24 | — | — | US | disclosed |
| EP-2493871-B1 | NOVEL OXIME DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2014-09-03 | — | — | EP | disclosed |
| EP-1405852-B9 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2013-03-27 | — | — | EP | disclosed |
| US-20120277212-A1 | Novel Oxime Derivatives and Their Use As Allosteric Modulators of Metabotropic Glutamate Receptors | PRESTWICK CHEMICAL, INC. (FR) | 2012-11-01 | — | — | US | disclosed |
| EP-1577301-B1 | Antithrombotic diaminocyclohexane derivatives | DAIICHI SANKYO CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| EP-2493871-A1 | NOVEL OXIME DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Domain Therapeutics (FR) | 2012-09-05 | — | — | EP | disclosed |
| EP-1405852-B1 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2012-08-01 | — | — | EP | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| US-20080015215-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20080015215-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20080015215-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-09 | — | — | US | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | F2, C1S, C9 | LCK 4440/4885ABL1 3056/4885MAPK1 2214/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | LCK 3678/4885ABL1 1845/4885MAPK1 1864/4885 |
| US-20080015215-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | LCK 3678/4885ABL1 1845/4885MAPK1 1864/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | LCK 3678/4885ABL1 1845/4885MAPK1 1864/4885 |
| US-20120277212-A1 | Novel Oxime Derivatives and Their Use As Allosteric Modulators of Metabotropic Glutamate Receptors | GRM4, GRM1, GRM2 | LCK 1377/4885ABL1 2977/4885MAPK1 780/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | LCK 3678/4885ABL1 1845/4885MAPK1 1864/4885 |
| US-20110312990-A1 | Diamine Derivatives | C9, C1S, C1R | LCK 3505/4885ABL1 1845/4885MAPK1 1758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.